Please login to the form below

Not currently logged in
Email:
Password:

Xarelto effective in reducing blood clots

A study shows that following total knee replacement surgery, Xarelto reduces the relative risk of blood clots when compared with enoxaparin

A study published in The Lancet shows that following total knee replacement surgery, Xarelto (rixaroxoban) reduces the relative risk of blood clots by more than 30 per cent when compared with enoxaparin.

The results come from the Phase III RECORD4 trial comparing Bayer's anticoagulant Xarelto, administered as a once-daily tablet with enoxaprin, a twice-daily injection.

Professor Beverley Hunt, consultant haematologist and medical director of Lifeblood said: "We want to ensure that every adult admitted to hospital in the UK receives appropriate prevention against hospital-acquired clots, which are the number one cause of preventable deaths in hospital care. We welcome rivaroxaban which has the advantages of being a tablet and has proven to be superior to the gold standard in clinical trials after knee replacements"

As Xarelto is in tablet form it does not need to be administered by a healthcare practitioner, unlike the injectable, twice-daily enoxaparin.

"Blood clots after major orthopaedic surgery remain a serious clinical problem," said Professor Ajay Kakkar, professor of surgical sciences at the Barts and the London School of Medicine and Dentistry, and director of the Thrombosis Research Institute. "Rivaroxaban will add to our armamentarium of thrombosis-preventing strategies and help in their use after hospital discharge," he continued.

Xarelto is approved in the EU, among other countries, for the prevention of venous thromboembolism (VTE) in adults undergoing elective hip or knee replacement surgery.

6th May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics